Earnings summaries and quarterly performance for Ginkgo Bioworks Holdings.
Executive leadership at Ginkgo Bioworks Holdings.
Board of directors at Ginkgo Bioworks Holdings.
Research analysts who have asked questions during Ginkgo Bioworks Holdings earnings calls.
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
3 questions for DNA
Also covers: ABCL, ABSI, ARWR +19 more
Mark Massaro
BTIG, LLC
3 questions for DNA
Also covers: ADPT, AKYA, BLLN +19 more
Elizabeth Koslosky
Goldman Sachs
2 questions for DNA
Also covers: A, NAUT
ML
Matthew Larew
William Blair & Company
2 questions for DNA
Also covers: AMED, ATR, MASS +10 more
TS
Tejas Savant
Morgan Stanley
2 questions for DNA
Also covers: ADPT, AKYA, AVTR +19 more
JK
Jacqueline Kisa
TD Cowen
1 question for DNA
Also covers: ABCL, OABI
JL
Jason Lai
Citigroup
1 question for DNA
Also covers: MYGN, NAUT, SEER
John Kim
BMO Capital Markets
1 question for DNA
Also covers: AIV, ALX, ARDX +32 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
1 question for DNA
Also covers: A, ADPT, AVTR +21 more
Michael Ryskin
Bank of America Merrill Lynch
1 question for DNA
Also covers: A, ALGN, AVTR +28 more
Recent press releases and 8-K filings for DNA.
Ginkgo Bioworks Announces Q3 2025 Financial Results and Reaffirms FY2025 Guidance
DNA
Earnings
Guidance Update
Demand Weakening
- Ginkgo Bioworks reported total revenue of $39 million for Q3 2025, a 56% decrease compared to Q3 2024, with Cell Engineering revenue at $29 million and Biosecurity revenue at $9 million.
- The company's GAAP net loss was $81 million and Adjusted EBITDA was ($56 million) for Q3 2025.
- Ginkgo maintained a strong financial position with $462 million in cash, cash equivalents, and marketable securities as of Q3 2025, and reported a quarterly cash burn of $28 million in Q3 2025, indicating continued improvement.
- The company reaffirmed its total revenue guidance for FY2025 to be between $167 million and $187 million.
Nov 6, 2025, 9:30 PM
Ginkgo Bioworks Provides Q3 2025 Financial and Strategic Update
DNA
Earnings
Guidance Update
New Projects/Investments
- Ginkgo Bioworks reported a strong cash position of $462 million in cash and cash equivalents with no bank debt after Q3 2025.
- The company significantly reduced its quarterly cash burn to $28 million in Q3 2025, a 75% decrease from Q3 2024, primarily due to restructuring efforts.
- Ginkgo reaffirmed its full-year 2025 revenue guidance, expecting $167-$187 million in total revenue, with cell engineering revenue projected at $117-$137 million and biosecurity revenue at at least $40 million.
- Strategic objectives for 2026 include delivering robotics and software for autonomous labs to customers, expanding its Boston-based autonomous lab, and enhancing CRO services and Data Points offerings by leveraging its in-house robotic infrastructure.
- In October 2025, Ginkgo reset its Google Cloud contract, reducing future commitments by over $100 million and extending the agreement period to six years.
Nov 6, 2025, 9:30 PM
Ginkgo Bioworks Reports Third Quarter 2025 Financial Results and Reaffirms Full Year Guidance
DNA
Earnings
Guidance Update
New Projects/Investments
- Ginkgo Bioworks Holdings reported Total revenue of $39 million for the third quarter ended September 30, 2025, representing a 56% decrease from the comparable prior year period, and a GAAP net loss of $(81) million.
- As of September 30, 2025, the company maintained a balance of $462 million in cash, cash equivalents, and marketable securities.
- For the full year 2025, Ginkgo reaffirms its Total revenue guidance of $167-$187 million, with Cell Engineering revenue expected to be $117-$137 million and Biosecurity revenue projected to be at least $40 million.
- Recent business highlights include the extension of its multi-year strategic partnership with Bayer and being awarded a project agreement through BARDA's BioMaP-Consortium with a total contract value of up to $22.2 million.
Nov 6, 2025, 9:05 PM
Ginkgo Bioworks Awarded BARDA Contract
DNA
New Projects/Investments
- Ginkgo Bioworks has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium).
- The project, with a total contract value of up to $22.2 million, aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) to protect against and treat filoviruses like Ebola and Sudan Viruses.
- Ginkgo will lead a team comprising Advanced BioScience Laboratories (ABL), Inc., Isolere Bio by Donaldson, NeuImmune, Inc., and ProteoNic BV to produce the anti-filovirus mAbs cocktail of 1C3 and 1C11.
Nov 3, 2025, 1:00 PM
Quarterly earnings call transcripts for Ginkgo Bioworks Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more